MedPath

Post-market Clinical Follow-up on the balanSys UNI Knee Prosthesis Implanted With a Spacer Block Surgical Technique

Active, not recruiting
Conditions
Knee Arthropathy
Registration Number
NCT04598568
Lead Sponsor
Mathys Ltd Bettlach
Brief Summary

The purpose of the study is the evaluation of the clinical and radiological long-term performance of the balanSys UNI fix in a multicenter routine clinical setting.

Detailed Description

Prospective multicenter follow-up study which examines the short- to long-term post-market clinical data on the safety and performance of the balanSys UNI fix knee prosthesis.

In total at least 100 participants in 3 clinics are included in this multicenter study.

The primary endpoint of the study is the Knee Society Score (KSS) 2 years after surgery.

The following parameters will be collected during the regular clinical and radiological follow-up: Knee Society Score, Knee and Osteoarthritis Outcome Score (KOOS), radiographic evaluation and detection of adverse events.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
116
Inclusion Criteria
  • Informed consent form (signed by participant and investigator)
  • Primary implantation
  • Age at inclusion: Between 18 and 90 years old
  • Willing to participate in the follow-up
Exclusion Criteria
  • Missing Informed consent form
  • Known or suspected non-compliance (e.g. drug or alcohol abuse)
  • Enrollment of the investigator, his/her family, employees and other dependent persons
  • Patient younger than 18 years old
  • Revision surgery
  • Does have a known allergy to metal in medical devices
  • Suffers from ACL rupture
  • Pregnancy or in the breast feeding period

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Knee Society Score2 years

The primary endpoint of the study is the Knee Society Score (KSS) 2 years after surgery

The Knee Society Score consists of an objective score (0-100 points) and a score for function (0-100 points).

A higher score means a better outcome.

Secondary Outcome Measures
NameTimeMethod
Radiographic evaluation of lucent lines6-12 weeks - 10 years

The second endpoint of interest is the incidence of lucent lines measured in millimeters by means of standard X-rays.

Adverse Events and Complications6-12 weeks - 10 years

Documentation of complication(s):

- Description of complication with the UKA

Documentation of component revision(s) (Adverse Events):

* Reason(s) for revision(s)

* Revised component(s)

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.